HIB Vaccine

Haemophilus influenzae type b

Vaccine Linked with Diabetes

The British Medical Journal warns about the dangers of childhood vaccines. Investigators pooled data on roughly 116,000 Finnish children who received Heamophisis Influenza type b vaccine at either 3 or 24 months of age. These children were compared with 128,5000 children who did not receive the vaccine.

Subjects were reevaluated at age 10. The study's author found that "immunizations starting after the age of 2 months is associated with an increased risk of diabetes. Our analysis is further associated with a similar rise in diabetis after immunization with H influenzae type b vaccine in the US and UK. Furthermore, the increased risk of of diabetes in the vaccinated group exceeds the expected decreased risk of complication of H influenzae meningitis"

Research into immunisation has been based on the theory that the benefits of immunisation far outweigh the risks from delayed adverse events and so long term safety studies do not need to be performed. When looking at diabetes - only one potential chronic adverse event - we found that the rise in the prevalence of diabetes may more than offset the expected decline in long term complications of H influenzae meningitis. Thus diabetes induced by vaccine should not be considered a rare potential adverse event. The incidence of many other chronic immunological diseases, including asthma, allergies, and immune mediated cancers, has risen rapidly and may also be linked to immunisation.


Classen JB, Claussen DC   Public should be told that vaccines may have long term adverse effects   Brit Med Journal 1999 (Jan 16);   318 (7177):   193 ~ FULL TEXT



The C.D.C A.C.I.P. recommends Hib vaccination at ages 2, 4, 6, 12 or 15   months and between 4-6 years old (before school entry) MMWR Jan 11, 1991, Vol. 40, No. RR-1, pp. 1-7.

Hib is a bacterial infection, which has been associated with meningitis, epiglottitis, cellulitis, septic arthritis, osteomyelitis, percarditis and pneumonia. About 75% of all forms of Hib occur in children less than 18 months of age. The Hib vaccine can cause adverse reactions such as convulsions, allergic reactions such as anaphylaxis, vomiting, and serum sickness-like reactions. The FDA did not recognize these reactions when licensure was granted. Incidence of Hib type meningitis peaks between 6-11 months.

Daum RS, Sood SK, Osterholm, MT et. al.   Decline in serum antibody to the capsule of Haemophilus influenzae type b in the immediate postimmunization period   J Pediatr. 1989 (May);   114 (5):   742-747

Milstien JB, Gross TP, Kuritsky JN   Adverse reactions reported following receipt of Haemophilus influenzae type b vaccine: an analysis after 1 year of marketing   Pediatrics 1987 (Aug);   80 (2):   270-274



The "Finnish" study, upon which license was granted, showed the vaccine was  ineffective for infants 3-17 months of age.

Peltola H, Kayhty H, Sivonen A, Makela H   Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland   Pediatrics 1977 (Nov);   60 (5):   730-737

Shinefield HR, Hiatt RA, Fireman BH   Efficacy of Haemophilus influenzae type b capsular polysaccharide vaccine   Pediatr Infect Dis J. 1988 (Mar);   7 (3):   149-156

Shapiro ED, Murphy TV, Wald ER, Brady CA   The protective efficacy of Haemophilus b polysaccharide vaccine   JAMA. 1988 (Sep 9);   260 (10):   1419-1422

Harrison LH, Broome CV, Hightower AW, Hoppe CC, Makintubee S, Sitze SL,  A day care-based study of the efficacy of Haemophilus b polysaccharide vaccine   JAMA 1988 (Sep 9);   260 (10):   1413-1418



Other studies showed the vaccine has no efficacy at all.

Ward JI, Broome CV, Harrison LH, Shinefield H, Black S   Haemophilus influenzae type b vaccines: lessons for the future   Pediatrics 1988 (Jun);   81 (6):   886-893

Osterholm MT, Rambeck JH, White KE, Jacobs JL, Pierson LM, Neaton JD, Hedberg   Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota   JAMA 1988 (Sep 9);   260 (10):   1423-1428

Ward J, Brenneman G, Letson GW, Heyward WL   Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group   N Engl J Med 1990 (Nov 15);   323 (20):   1393-1401



The C.D.C. stated "Efficacy of the conjugate vaccine (currently being used) has not been determined in field trials.

MMWR 1988, Vol. 37, RR-37, pp. 13-16.



Your baby will actually become more susceptible to meningitis for up to 3 weeks following vaccination.

Daum RS, Sood SK, Osterholm, MT et. al.   Decline in serum antibody to the capsule of Haemophilus influenzae type b in the immediate postimmunization period   J Pediatr. 1989 (May);   114 (5):   742-747

Ward J, Brenneman G, Letson GW, Heyward WL   Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group   N Engl J Med 1990 (Nov 15);   323 (20):   1393-1401

Sood SK, Schreiber JR, Siber GR, Daum RS   Postvaccination susceptibility to invasive Haemophilus influenzae type b disease in infant rats   J Pediatr 1988 (Nov);   113 (5):   814-819

Hiner EE, Frasch CE   Spectrum of disease due to Haemophilus influenzae type b occurring in vaccinated children   J Infect Dis 1988 (Aug);   158 (2):   343-348

Granoff DM, Shackelford PG, Suarez BK, Nahm MH et. al. Hemophilus influenzae type B disease in children vaccinated with type B polysaccharide vaccine N Engl J Med 1986 Dec 18;315(25):1584-1590

Ward J   Newer Haemophilus influenzae type b vaccines and passive prophylaxis   Pediatr Infect Dis J. 1987 (Aug);   6 (8):   799-803



The risk of contracting meningitis one week after vaccination is 6.4-1.8 times greater than unvaccinated children.

Sood SK, Schreiber JR, Siber GR, Daum RS   Postvaccination susceptibility to invasive Haemophilus influenzae type b disease in infant rats   J Pediatr 1988 (Nov);   113 (5):   814-819



41% of cases of Hib occurred in vaccinated individuals. The vaccine's protective efficacy is about negative 58%. In other words, you are more likely to get Hib if you are vaccinated

Osterholm MT, Rambeck JH, White KE, Jacobs JL, Pierson LM, Neaton JD, Hedberg   Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota   JAMA 1988 (Sep 9);   260 (10):   1423-1428



The widespread use of the Hemophilus influenza vaccine in 1986 was followed by a 62% rise (16 cases/100,000 children to 29.2 cases/100,000) in the incidence of diabetes in the 0-4 age group between the years 1980-1982 and 1990-1992.

Tuomilehto J, Virtala E, Karvonen M, Lounamaa R, Pikaniemi J et. al.   Increase in incidence of insulin-dependent diabetes mellitus among children in Finland   Int J Epidemiol 1995 (Oct);   24 (5):   984-992



The incidence of IDDM also rose in the young children 2-3 year olds after the first dose of HiB was introduced.

Classen DC, Classen JB   The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus   Infectious Diseases in Clinical Practice 1997;   6:   449-454



Drastic rises in the incidence of IDDM have been reported in the US and the UK after the introduction of the HiB vaccine. An epidemic of diabetes in the 0-4 age group occurred during the years 1985-1989 in Allegheny county at the time when the Hemophilus influenza vaccine was being incorporated into the immunization schedule. The annual incidence of IDDM in 0-4 year  olds living in Allegheny county rose 60% from the years 1980-1984 (10 cases/100,000) to 1985-1989 (16 cases/100,000). The incidence of diabetes in  0-4 year olds had been consistently below 10 cases/100,000 from 1965-1984.  The incidence of IDDM in this age group is expected to rise even higher since  the maximum effect of the HiB vaccine on IDDm is not seen until 4 years after  immunization.

Dokheel TM   An epidemic of childhood diabetes in the United States? Evidence from Allegheny County, Pennsylvania.Pittsburgh Diabetes Epidemiology Research Group   Diabetes Care 1993 (Dec);   16 (12):   1606-1611

Brewster D   The epidemiology of Haemophilus influenzae invasive disease in Scotland prior to immunisation   Health Bull (Edinb) 1993 (Nov);   51 (6):   385-393



In 1982, the C.D.C., the F.D.A., and the manufacturer created a surveillance system to monitor spontaneous reports of adverse events occurring after inoculation with the new-plasma derived hepatitis B vaccine (Heptavax-B, Merck Sharp and Dohme, West Point, PA). In the three years between June 1, 1982 and May 31, 1985, an estimated 850,000 persons received the vaccine. During that period, a total of 41 reports were received for one of the following neurologic adverse events: convulsions (5 cases), Bell's palsy (10 cases), Guillain-Barre syndrome (9 cases), lumbar radiculopathy (5 cases), brachial plexus neuropathy (3 cases), optic neuritis (5 cases), and transverse myelitis (4 cases).  Half of these occurred after the first of three required vaccine doses. In some analyses, Gullain-Barre syndrome was reported significantly more often that expected (p=<0.05).

Shaw FE, Jr., Graham DJ, Guess HA, Milstien JB et. al.   Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years   Am J Epidemiol 1988 (Feb);   127 (2):   337-352